Skip to main content

Table 3 Specification of the primary models for overall survival, locoregional control and freedom from distant metastasis

From: Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study

Prognostic factors to be included in the primary models
Overall survival model Locoregional control model Freedom from distant metastasis model
1 N stage: N0 vs N+ Sex: female vs male N stage: N0 vs N+
2 T stage: T1–2 vs T3–4 N stage: N0 vs N+ T stage: T1–2 vs T3–4
3 Sex: female vs Male T stage: T1–2 vs T3–4 Sex: female vs male
4 Age: modelled as a continuous, linear factor Age: modelled as a continuous, linear factor Age: modelled as a continuous, linear factor
5 Primary tumour GTV (cm3): modelled as a continuous, log-transformed factor Primary tumour GTV (cm3): modelled as a continuous, log-transformed factor Primary tumour GTV (cm3): modelled as a continuous, log-transformed factor
6 Primary tumour dose (EQD2): modelled as a continuous, linear factor Primary tumour dose (EQD2): modelled as a continuous, linear factor Primary tumour dose (EQD2): modelled as a continuous, linear factor
7 Histology: SCC vs basaloid SCC Histology: SCC vs basaloid SCC Histology: SCC vs basaloid SCC
8 Chemotherapy regimen: [no chemotherapy] vs [mitomycin C-based regimen] vs [cisplatin-based regimen] Chemotherapy regimen: [no chemotherapy] vs [mitomycin C-based regimen] vs [icsplatin-based regimen]; Chemotherapy regimen: [no chemotherapy] vs [mitomycin C-based regimen] vs [cisplatin-based regimen];
9 RT technique: [3D-CRT] vs [IMRT] vs [VMAT] RT technique: 3D-CRT vs IMRT vs VMAT RT technique: 3D-CRT vs IMRT vs VMAT
  1. N stage nodal stage, T stage tumour stage, GTV Gross tumour volume, EQD2 Equivalent dose in 2 Gy fractions (α/β = 10 Gy), SCC Squamous cell carcinoma, 3D-CRT Three-dimensional conformal radiation therapy, IMRT Intensity-modulated radiation therapy, VMAT Volumetric modulated arc therapy